RxDoctor Payments DataLook up a doctor →

Marc Roelke, MD

Clinical Cardiac Electrophysiology · West Orange, NJNPI 1851391429

Payments from drug & device makers

$145,874in general payments, 2019–2025

Across 531 payments — averaging $274.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$93K
  • Boston Scientific$16K
  • Johnson & Johnson$13K
  • Medtronic$12K
  • Boehringer Ingelheim$5K
  • Pfizer$3K
  • plus $4K from 30 others
$475in research payments, 2019–2025

Across 1 payment — averaging $475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$475

What the payments were for

  • Consulting fees$82,63875%
  • Speaking & faculty fees$14,48113%
  • Travel & lodging$5,5525%
  • Food & beverage$7,1186%
  • Education$200%
  • Entertainment$640%
  • Other$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,874 in reported general payments places this provider in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$378,905
Medicare patients
2,243
Services billed
6,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$106,116
XareltoRivaroxaban26$25,640
EntrestoSacubitril/Valsartan22$20,456
Coreg CrCarvedilol Phosphate12$14,295
JardianceEmpagliflozin13$10,674
PradaxaDabigatran Etexilate Mesylate21$3,883
Amiodarone Hcl83$2,398
Metoprolol Succinate129$1,857
Flecainide Acetate16$835
Carvedilol67$819
SotalolSotalol Hcl34$657
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$604
Atorvastatin Calcium48$462
Losartan Potassium32$410
Rosuvastatin Calcium33$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,044$106,11699 claims
Johnson & JohnsonXarelto$13,172$25,64026 claims
NovartisEntresto$541$20,45622 claims
Boehringer IngelheimJardiance, Pradaxa$4,698$14,55834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →